Key facts
- This page summarizes Glorious Finance Ltd's Form 3 filing for CytoMed Therapeutics Ltd (GDTC).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Apr 2023, 16:49.
Glorious Finance Ltd - 31 Mar 2023 Form 3 Insider Report for CytoMed Therapeutics Ltd (GDTC)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- GDTC
- Reported as of
- 31 Mar 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Chee Kong Choo Director
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Glorious Finance Ltd filed Form 3 for CytoMed Therapeutics Ltd (GDTC) on 14 Apr 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GDTC
holding
Ordinary Shares, no par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,653,604
- Date
- 31 Mar 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Mr. CHOO Chee Kong does not directly hold any shares in our Company but is deemed to beneficially own the shares held by Glorious Finance as indicated in the table above. Mr. CHOO Chee Kong owns 55.0% of shares in Glorious Finance. Glorious Finance is a major shareholder of the Company.